Successful ABO Incompatible Living Donor Liver Transplantation in a Patient With High Isoagglutinin Titer Using High-Dose Intravenous Immunoglobulin

2007 ◽  
Vol 39 (10) ◽  
pp. 3491-3494 ◽  
Author(s):  
T. Ikegami ◽  
A. Taketomi ◽  
Y. Soejima ◽  
T. Iguchi ◽  
K. Sanefuji ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Intravenous Immunoglobulin ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
High Dose ◽  
Donor Liver ◽  
Donor Liver Transplantation

scholarly journals Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Steffen Hartleif ◽  
Michael Schumm ◽  
Michaela Döring ◽  
Markus Mezger ◽  
Peter Lang ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Survival ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Immunosuppressive Treatment ◽  
Pilot Trial ◽  
High Dose ◽  
Donor Liver ◽  
Open Label ◽  
Donor Liver Transplantation

Background. Calcineurin inhibitors (CNI) have significantly improved patient and graft survival in pediatric liver transplantation (pLT). However, CNI toxicity leads to significant morbidity. Moreover, CNIs cannot prevent long-term allograft injury. Mesenchymal stem (stromal) cells (MSC) have potent immunomodulatory properties, which may promote allograft tolerance and ameliorate toxicity of high-dose CNI. The MYSTEP1 trial aims to investigate safety and feasibility of donor-derived MSCs in pLT. Methods/Design. 7 to 10 children undergoing living-donor pLT will be included in this open-label, prospective pilot trial. A dose of 1 × 106 MSCs/kg body weight will be given at two time points: first by intraportal infusion intraoperatively and second by intravenous infusion on postoperative day 2. In addition, participants will receive standard immunosuppressive treatment. Our primary objective is to assess the safety of intraportal and intravenous MSC infusion in pLT recipients. Our secondary objective is to evaluate efficacy of MSC treatment as measured by the individual need for immunosuppression and the incidence of biopsy-proven acute rejection. We will perform detailed immune monitoring to investigate immunomodulatory effects. Discussion. Our study will provide information on the safety of donor-derived MSCs in pediatric living-donor liver transplantation and their effect on immunomodulation and graft survival.

Adult-to-Adult Living-Donor Liver Transplantation

Swiss Surgery ◽  
2003 ◽  
Vol 9 (5) ◽  
pp. 227-236 ◽  
Author(s):  
Majno ◽  
Mentha ◽  
Berney ◽  
Bühler ◽  
Giostra ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Therapeutic Option ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Multidisciplinary Program ◽  
First Case ◽  
Living Donor Transplantation ◽  
The Right

Living donor liver transplantation is a relatively new procedure in which the right side of the liver is harvested in a healthy donor and transplanted into a recipient. After the first case in 1994, over 3000 cases have been done worldwide. This review summarizes the reasons why the procedure is needed, describes its main technical aspects, highlights the boundaries in which it can be done safely, summarizes the current experience worldwide and describes the main points of the program in our unit. We argue that living-donor transplantation is a viable alternative to a long time on the waiting list for several patients, and it can be performed safely and successfully provided that all precautions are undertaken to minimize the risks in the donor and to increase the chances of a good outcome in the recipients. If these prerequisites are met, and within the framework of a structured multidisciplinary program, we believe that living-donor liver transplantation should be funded by health insurances as a recognized therapeutic option.

Sign in / Sign up

Export Citation Format

Share Document